Global healthcare company Abbott (ABT) Thursday said the XIENCE Xpedition Everolimus Eluting Coronary Stent System received U.S. Food and Drug Administration approval and is launching immediately in the United States. XIENCE Xpedition comes with a new stent delivery system designed to optimize deliverability, especially in case of challenging coronary anatomies, said Abbott.
Samin Sharma, M.D., director of Clinical and Interventional Cardiology, dean of International Clinical Affiliations, and president of the Mount Sinai Heart Network at Mount Sinai Medical Center, New York became the first physician to implant a patient with XIENCE Xpedition in the United States.
"XIENCE Xpedition represents a powerful combination of deliverability, strong clinical data and broad availability of meaningful sizes - three factors that make this product well-suited to treat a wide range of patients," said Dr. Sharma.
Abbott's XIENCE drug eluting stents, including the newly approved XIENCE Xpedition, are the first and only drug eluting stents in the U.S. market to be proven safe for direct stenting, a technique in which the stent system is not preceded by another device to prepare the lesion and has the potential to save time and resources in the catheterization laboratory, said the company.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.